<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33931083</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1756-6606</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Apr</Month><Day>30</Day></PubDate></JournalIssue><Title>Molecular brain</Title><ISOAbbreviation>Mol Brain</ISOAbbreviation></Journal><ArticleTitle>Ablation of interleukin-19 improves motor function in a mouse model of amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>74</StartPage><MedlinePgn>74</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">74</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13041-021-00785-8</ELocationID><Abstract><AbstractText>Neuroinflammation by activated microglia and astrocytes plays a critical role in progression of amyotrophic lateral sclerosis (ALS). Interleukin-19 (IL-19) is a negative-feedback regulator that limits pro-inflammatory responses of microglia in an autocrine and paracrine manner, but it remains unclear how IL-19 contributes to ALS pathogenesis. We investigated the role of IL-19 in ALS using transgenic mice carrying human superoxide dismutase 1 with the G93A mutation (SOD1<sup>G93A</sup> Tg mice). We generated IL-19-deficient SOD1<sup>G93A</sup> Tg (IL-19<sup>-/-</sup>/SOD1<sup>G93A</sup> Tg) mice by crossing SOD1<sup>G93A</sup> Tg mice with IL-19<sup>-/-</sup> mice, and then evaluated disease progression, motor function, survival rate, and pathological and biochemical alternations in the resultant mice. In addition, we assessed the effect of IL-19 on glial cells using primary microglia and astrocyte cultures from the embryonic brains of SOD1<sup>G93A</sup> Tg mice and IL-19<sup>-/-</sup>/SOD1<sup>G93A</sup> Tg mice. Expression of IL-19 in primary microglia and lumbar spinal cord was higher in SOD1<sup>G93A</sup> Tg mice than in wild-type mice. Unexpectedly, IL-19<sup>-/-</sup>/SOD1<sup>G93A</sup> Tg mice exhibited significant improvement of motor function. Ablation of IL-19 in SOD1<sup>G93A</sup> Tg mice increased expression of both neurotoxic and neuroprotective factors, including tumor necrosis factor-&#x3b1; (TNF-&#x3b1;), IL-1&#x3b2;, glial cell line-derived neurotrophic factor (GDNF), and transforming growth factor &#x3b2;1, in lumbar spinal cord. Primary microglia and astrocytes from IL-19<sup>-/-</sup>/SOD1<sup>G93A</sup> Tg mice expressed higher levels of TNF-&#x3b1;, resulting in release of GDNF from astrocytes. Inhibition of IL-19 signaling may alleviate ALS symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Komiya</LastName><ForeName>Hiroyasu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takeuchi</LastName><ForeName>Hideyuki</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-5912-7581</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan. htake@yokohama-cu.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ogawa</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Kosuke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ogasawara</LastName><ForeName>Akihiro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Keita</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azuma</LastName><ForeName>Yasu-Taka</ForeName><Initials>YT</Initials><AffiliationInfo><Affiliation>Laboratory of Veterinary Pharmacology, Division of Veterinary Science, Osaka Prefecture University Graduate School of Life and Environmental Science, Izumisano, Osaka, 598-9531, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doi</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Fumiaki</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan. ftanaka@yokohama-cu.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Brain</MedlineTA><NlmUniqueID>101468876</NlmUniqueID><ISSNLinking>1756-6606</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051100">Glial Cell Line-Derived Neurotrophic Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498891">Il19 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007378">Interleukins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018123">Receptors, Interleukin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017353" MajorTopicYN="Y">Gene Deletion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051100" MajorTopicYN="N">Glial Cell Line-Derived Neurotrophic Factor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018836" MajorTopicYN="N">Inflammation Mediators</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007378" MajorTopicYN="N">Interleukins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008136" MajorTopicYN="N">Longevity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008159" MajorTopicYN="N">Lumbar Vertebrae</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018123" MajorTopicYN="N">Receptors, Interleukin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Astrocyte</Keyword><Keyword MajorTopicYN="N">Interleukin-19</Keyword><Keyword MajorTopicYN="N">Microglia</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>1</Day><Hour>5</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33931083</ArticleId><ArticleId IdType="pmc">PMC8086093</ArticleId><ArticleId IdType="doi">10.1186/s13041-021-00785-8</ArticleId><ArticleId IdType="pii">10.1186/s13041-021-00785-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Traxinger K, Kelly C, Johnson BA, Lyles RH, Glass JD. Prognosis and epidemiology of amyotrophic lateral sclerosis: Analysis of a clinic population, 1997&#x2013;2011. Neurol Clin Pract. 2013;3(4):313&#x2013;320. doi: 10.1212/CPJ.0b013e3182a1b8ab.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/CPJ.0b013e3182a1b8ab</ArticleId><ArticleId IdType="pmc">PMC3787117</ArticleId><ArticleId IdType="pubmed">24195020</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasco S, Zaragoza P, Garcia-Redondo A, Calvo AC, Osta R. Inflammatory and non-inflammatory monocytes as novel prognostic biomarkers of survival in SOD1G93A mouse model of Amyotrophic Lateral Sclerosis. PLoS ONE. 2017;12(9):e0184626. doi: 10.1371/journal.pone.0184626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0184626</ArticleId><ArticleId IdType="pmc">PMC5591000</ArticleId><ArticleId IdType="pubmed">28886177</ArticleId></ArticleIdList></Reference><Reference><Citation>Musaro A. State of the art and the dark side of amyotrophic lateral sclerosis. World J Biol Chem. 2010;1(5):62&#x2013;68. doi: 10.4331/wjbc.v1.i5.62.</Citation><ArticleIdList><ArticleId IdType="doi">10.4331/wjbc.v1.i5.62</ArticleId><ArticleId IdType="pmc">PMC3083964</ArticleId><ArticleId IdType="pubmed">21540991</ArticleId></ArticleIdList></Reference><Reference><Citation>Pramatarova A, Laganiere J, Roussel J, Brisebois K, Rouleau GA. Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J Neurosci. 2001;21(10):3369&#x2013;3374. doi: 10.1523/JNEUROSCI.21-10-03369.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.21-10-03369.2001</ArticleId><ArticleId IdType="pmc">PMC6762496</ArticleId><ArticleId IdType="pubmed">11331366</ArticleId></ArticleIdList></Reference><Reference><Citation>Clement AM, Nguyen MD, Roberts EA, Garcia ML, Boillee S, Rule M, McMahon AP, Doucette W, Siwek D, Ferrante RJ, et al. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science. 2003;302(5642):113&#x2013;117. doi: 10.1126/science.1086071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1086071</ArticleId><ArticleId IdType="pubmed">14526083</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher G, Dickensheets H, Eskdale J, Izotova LS, Mirochnitchenko OV, Peat JD, Vazquez N, Pestka S, Donnelly RP, Kotenko SV. Cloning, expression and initial characterization of interleukin-19 (IL-19), a novel homologue of human interleukin-10 (IL-10) Genes Immun. 2000;1(7):442&#x2013;450. doi: 10.1038/sj.gene.6363714.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.gene.6363714</ArticleId><ArticleId IdType="pubmed">11196675</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabat R, Wallace E, Endesfelder S, Wolk K. IL-19 and IL-20: two novel cytokines with importance in inflammatory diseases. Expert Opin Ther Targets. 2007;11(5):601&#x2013;612. doi: 10.1517/14728222.11.5.601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14728222.11.5.601</ArticleId><ArticleId IdType="pubmed">17465720</ArticleId></ArticleIdList></Reference><Reference><Citation>Parrish-Novak J, Xu W, Brender T, Yao L, Jones C, West J, Brandt C, Jelinek L, Madden K, McKernan PA, et al. Interleukins 19, 20, and 24 signal through two distinct receptor complexes. Differences in receptor-ligand interactions mediate unique biological functions. J Biol Chem. 2002;277(49):47517&#x2013;47523. doi: 10.1074/jbc.M205114200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M205114200</ArticleId><ArticleId IdType="pubmed">12351624</ArticleId></ArticleIdList></Reference><Reference><Citation>Horiuchi H, Parajuli B, Wang Y, Azuma YT, Mizuno T, Takeuchi H, Suzumura A. Interleukin-19 acts as a negative autocrine regulator of activated microglia. PLoS ONE. 2015;10(3):e0118640. doi: 10.1371/journal.pone.0118640.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0118640</ArticleId><ArticleId IdType="pmc">PMC4368203</ArticleId><ArticleId IdType="pubmed">25794104</ArticleId></ArticleIdList></Reference><Reference><Citation>Azuma YT, Matsuo Y, Kuwamura M, Yancopoulos GD, Valenzuela DM, Murphy AJ, Nakajima H, Karow M, Takeuchi T. Interleukin-19 protects mice from innate-mediated colonic inflammation. Inflamm Bowel Dis. 2010;16(6):1017&#x2013;1028. doi: 10.1002/ibd.21151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ibd.21151</ArticleId><ArticleId IdType="pubmed">19834971</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooley ID, Chauhan VS, Donneyz MA, Marriott I. Astrocytes produce IL-19 in response to bacterial challenge and are sensitive to the immunosuppressive effects of this IL-10 family member. Glia. 2014;62(5):818&#x2013;828. doi: 10.1002/glia.22644.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22644</ArticleId><ArticleId IdType="pmc">PMC4076830</ArticleId><ArticleId IdType="pubmed">24677051</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuo Y, Azuma YT, Kuwamura M, Kuramoto N, Nishiyama K, Yoshida N, Ikeda Y, Fujimoto Y, Nakajima H, Takeuchi T. Interleukin 19 reduces inflammation in chemically induced experimental colitis. Int Immunopharmacol. 2015;29(2):468&#x2013;475. doi: 10.1016/j.intimp.2015.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2015.10.011</ArticleId><ArticleId IdType="pubmed">26476684</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimoto Y, Fujita T, Kuramoto N, Kuwamura M, Izawa T, Nishiyama K, Yoshida N, Nakajima H, Takeuchi T, Azuma YT. The role of interleukin-19 in contact hypersensitivity. Biol Pharm Bull. 2018;41(2):182&#x2013;189. doi: 10.1248/bpb.b17-00594.</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/bpb.b17-00594</ArticleId><ArticleId IdType="pubmed">29386478</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie W, Fang L, Gan S, Xuan H. Interleukin-19 alleviates brain injury by anti-inflammatory effects in a mice model of focal cerebral ischemia. Brain Res. 2016;1650:172&#x2013;177. doi: 10.1016/j.brainres.2016.09.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2016.09.006</ArticleId><ArticleId IdType="pubmed">27608956</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J, Wang H, Li L, Yuan Y, Shi X, Hou S. Treatment with IL-19 improves locomotor functional recovery after contusion trauma to the spinal cord. Br J Pharmacol. 2018;175(13):2611&#x2013;2621. doi: 10.1111/bph.14193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.14193</ArticleId><ArticleId IdType="pmc">PMC6003639</ArticleId><ArticleId IdType="pubmed">29500933</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao YC, Liang WG, Chen FW, Hsu JH, Yang JJ, Chang MS. IL-19 induces production of IL-6 and TNF-alpha and results in cell apoptosis through TNF-alpha. J Immunol. 2002;169(8):4288&#x2013;4297. doi: 10.4049/jimmunol.169.8.4288.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.169.8.4288</ArticleId><ArticleId IdType="pubmed">12370360</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu YH, Hsieh PP, Chang MS. Interleukin-19 blockade attenuates collagen-induced arthritis in rats. Rheumatology (Oxford) 2012;51(3):434&#x2013;442. doi: 10.1093/rheumatology/ker127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/ker127</ArticleId><ArticleId IdType="pubmed">21719423</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong H, Wu Y, Belardinelli L, Zeng D. A2B adenosine receptors induce IL-19 from bronchial epithelial cells, resulting in TNF-alpha increase. Am J Respir Cell Mol Biol. 2006;35(5):587&#x2013;592. doi: 10.1165/rcmb.2005-0476OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2005-0476OC</ArticleId><ArticleId IdType="pubmed">16778150</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX, et al. Motor neuron degeneration in mice that express a human Cu Zn superoxide dismutase mutation. Science. 1994;264(5166):1772&#x2013;1775. doi: 10.1126/science.8209258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi H, Mizoguchi H, Doi Y, Jin S, Noda M, Liang J, Li H, Zhou Y, Mori R, Yasuoka S, et al. Blockade of gap junction hemichannel suppresses disease progression in mouse models of amyotrophic lateral sclerosis and Alzheimer's disease. PLoS ONE. 2011;6(6):e21108. doi: 10.1371/journal.pone.0021108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0021108</ArticleId><ArticleId IdType="pmc">PMC3119678</ArticleId><ArticleId IdType="pubmed">21712989</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayworth CR, Gonzalez-Lima F. Pre-symptomatic detection of chronic motor deficits and genotype prediction in congenic B6.SOD1(G93A) ALS mouse model. Neuroscience. 2009;164(3):975&#x2013;985. doi: 10.1016/j.neuroscience.2009.08.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2009.08.031</ArticleId><ArticleId IdType="pmc">PMC2783710</ArticleId><ArticleId IdType="pubmed">19699279</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzumura A, Mezitis SG, Gonatas NK, Silberberg DH. MHC antigen expression on bulk isolated macrophage-microglia from newborn mouse brain: induction of Ia antigen expression by gamma-interferon. J Neuroimmunol. 1987;15(3):263&#x2013;278. doi: 10.1016/0165-5728(87)90121-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0165-5728(87)90121-4</ArticleId><ArticleId IdType="pmc">PMC7133952</ArticleId><ArticleId IdType="pubmed">3110208</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang J, Takeuchi H, Doi Y, Kawanokuchi J, Sonobe Y, Jin S, Yawata I, Li H, Yasuoka S, Mizuno T, et al. Excitatory amino acid transporter expression by astrocytes is neuroprotective against microglial excitotoxicity. Brain Res. 2008;1210:11&#x2013;19. doi: 10.1016/j.brainres.2008.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2008.03.012</ArticleId><ArticleId IdType="pubmed">18410911</ArticleId></ArticleIdList></Reference><Reference><Citation>Komiya H, Takeuchi H, Ogawa Y, Hatooka Y, Takahashi K, Katsumoto A, Kubota S, Nakamura H, Kunii M, Tada M, et al. CCR2 is localized in microglia and neurons, as well as infiltrating monocytes, in the lumbar spinal cord of ALS mice. Mol Brain. 2020;13(1):64. doi: 10.1186/s13041-020-00607-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-020-00607-3</ArticleId><ArticleId IdType="pmc">PMC7191738</ArticleId><ArticleId IdType="pubmed">32349774</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuno R, Yoshida Y, Nitta A, Nabeshima T, Wang J, Sonobe Y, Kawanokuchi J, Takeuchi H, Mizuno T, Suzumura A. The role of TNF-alpha and its receptors in the production of NGF and GDNF by astrocytes. Brain Res. 2006;1116(1):12&#x2013;18. doi: 10.1016/j.brainres.2006.07.120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2006.07.120</ArticleId><ArticleId IdType="pubmed">16956589</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Henkel JS, Zhang W, Urushitani M, Julien JP, Appel SH. Extracellular mutant SOD1 induces microglial-mediated motoneuron injury. Glia. 2010;58(2):231&#x2013;243. doi: 10.1002/glia.20919.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.20919</ArticleId><ArticleId IdType="pmc">PMC2784168</ArticleId><ArticleId IdType="pubmed">19672969</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JY, Lee JD, Phipps S, Noakes PG, Woodruff TM. Absence of toll-like receptor 4 (TLR4) extends survival in the hSOD1 G93A mouse model of amyotrophic lateral sclerosis. J Neuroinflammation. 2015;12:90. doi: 10.1186/s12974-015-0310-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-015-0310-z</ArticleId><ArticleId IdType="pmc">PMC4431460</ArticleId><ArticleId IdType="pubmed">25962427</ArticleId></ArticleIdList></Reference><Reference><Citation>Horiuchi H, Parajuli B, Komiya H, Ogawa Y, Jin S, Takahashi K, Azuma YT, Tanaka F, Suzumura A, Takeuchi H. Interleukin-19 abrogates experimental autoimmune encephalomyelitis by attenuating antigen-presenting cell activation. Front Immunol. 2021;12:615898. doi: 10.3389/fimmu.2021.615898.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.615898</ArticleId><ArticleId IdType="pmc">PMC7990911</ArticleId><ArticleId IdType="pubmed">33776998</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M, Re DB, Nagata T, Chalazonitis A, Jessell TM, Wichterle H, Przedborski S. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci. 2007;10(5):615&#x2013;622. doi: 10.1038/nn1876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1876</ArticleId><ArticleId IdType="pmc">PMC3799799</ArticleId><ArticleId IdType="pubmed">17435755</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensley K, Abdel-Moaty H, Hunter J, Mhatre M, Mou S, Nguyen K, Potapova T, Pye QN, Qi M, Rice H, et al. Primary glia expressing the G93A-SOD1 mutation present a neuroinflammatory phenotype and provide a cellular system for studies of glial inflammation. J Neuroinflammation. 2006;3:2. doi: 10.1186/1742-2094-3-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-3-2</ArticleId><ArticleId IdType="pmc">PMC1360663</ArticleId><ArticleId IdType="pubmed">16436205</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawaguchi-Niida M, Yamamoto T, Kato Y, Inose Y, Shibata N. MCP-1/CCR2 signaling-mediated astrocytosis is accelerated in a transgenic mouse model of SOD1-mutated familial ALS. Acta Neuropathol Commun. 2013;1:21. doi: 10.1186/2051-5960-1-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2051-5960-1-21</ArticleId><ArticleId IdType="pmc">PMC3893446</ArticleId><ArticleId IdType="pubmed">24252211</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuno R, Wang J, Kawanokuchi J, Takeuchi H, Mizuno T, Suzumura A. Autocrine activation of microglia by tumor necrosis factor-alpha. J Neuroimmunol. 2005;162(1&#x2013;2):89&#x2013;96. doi: 10.1016/j.jneuroim.2005.01.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2005.01.015</ArticleId><ArticleId IdType="pubmed">15833363</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi H, Jin S, Wang J, Zhang G, Kawanokuchi J, Kuno R, Sonobe Y, Mizuno T, Suzumura A. Tumor necrosis factor-alpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner. J Biol Chem. 2006;281(30):21362&#x2013;21368. doi: 10.1074/jbc.M600504200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M600504200</ArticleId><ArticleId IdType="pubmed">16720574</ArticleId></ArticleIdList></Reference><Reference><Citation>Horiuchi H, Parajuli B, Kawanokuchi J, Jin S, Mizuno T, Takeuchi H, Suzumura A. Oligomeric amyloid &#x3b2; facilitates microglial excitotoxicity by upregulating tumor necrosis factor-&#x3b1; and downregulating excitatory amino acid transporter 2 in astrocytes. Clin Exp Neuroimmunol. 2015;6(2):183&#x2013;190. doi: 10.1111/cen3.12192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cen3.12192</ArticleId></ArticleIdList></Reference><Reference><Citation>Brambilla L, Guidotti G, Martorana F, Iyer AM, Aronica E, Valori CF, Rossi D. Disruption of the astrocytic TNFR1-GDNF axis accelerates motor neuron degeneration and disease progression in amyotrophic lateral sclerosis. Hum Mol Genet. 2016;25(14):3080&#x2013;3095.</Citation><ArticleIdList><ArticleId IdType="pubmed">27288458</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortarolo M, Vallarola A, Lidonnici D, Battaglia E, Gensano F, Spaltro G, Fiordaliso F, Corbelli A, Garetto S, Martini E, et al. Lack of TNF-alpha receptor type 2 protects motor neurons in a cellular model of amyotrophic lateral sclerosis and in mutant SOD1 mice but does not affect disease progression. J Neurochem. 2015;135(1):109&#x2013;124. doi: 10.1111/jnc.13154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13154</ArticleId><ArticleId IdType="pubmed">25940956</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen SH, Oyarzabal EA, Sung YF, Chu CH, Wang Q, Chen SL, Lu RB, Hong JS. Microglial regulation of immunological and neuroprotective functions of astroglia. Glia. 2015;63(1):118&#x2013;131. doi: 10.1002/glia.22738.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22738</ArticleId><ArticleId IdType="pmc">PMC4237670</ArticleId><ArticleId IdType="pubmed">25130274</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Beers DR, Zhao W, Appel SH. Microglia in ALS: the good, the bad, and the resting. J Neuroimmune Pharmacol. 2009;4(4):389&#x2013;398. doi: 10.1007/s11481-009-9171-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-009-9171-5</ArticleId><ArticleId IdType="pubmed">19731042</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoll G, Jander S, Schroeter M. Cytokines in CNS disorders: neurotoxicity versus neuroprotection. J Neural Transm Suppl. 2000;59:81&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">10961421</ArticleId></ArticleIdList></Reference><Reference><Citation>Endo F, Komine O, Fujimori-Tonou N, Katsuno M, Jin S, Watanabe S, Sobue G, Dezawa M, Wyss-Coray T, Yamanaka K. Astrocyte-derived TGF-&#x3b2;1 accelerates disease progression in ALS mice by interfering with the neuroprotective functions of microglia and T cells. Cell Rep. 2015;11(4):592&#x2013;604. doi: 10.1016/j.celrep.2015.03.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2015.03.053</ArticleId><ArticleId IdType="pubmed">25892237</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakrabarty P, Li A, Ceballos-Diaz C, Eddy JA, Funk CC, Moore B, DiNunno N, Rosario AM, Cruz PE, Verbeeck C, et al. IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. Neuron. 2015;85(3):519&#x2013;533. doi: 10.1016/j.neuron.2014.11.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.11.020</ArticleId><ArticleId IdType="pmc">PMC4320003</ArticleId><ArticleId IdType="pubmed">25619653</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillot-Sestier MV, Doty KR, Gate D, Rodriguez J, Jr, Leung BP, Rezai-Zadeh K, Town T. Il10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology. Neuron. 2015;85(3):534&#x2013;548. doi: 10.1016/j.neuron.2014.12.068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.12.068</ArticleId><ArticleId IdType="pmc">PMC4352138</ArticleId><ArticleId IdType="pubmed">25619654</ArticleId></ArticleIdList></Reference><Reference><Citation>Moynagh PN. The interleukin-1 signalling pathway in astrocytes: a key contributor to inflammation in the brain. J Anat. 2005;207(3):265&#x2013;269. doi: 10.1111/j.1469-7580.2005.00445.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-7580.2005.00445.x</ArticleId><ArticleId IdType="pmc">PMC1571539</ArticleId><ArticleId IdType="pubmed">16185251</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakurai N, Kuroiwa T, Ikeuchi H, Hiramatsu N, Maeshima A, Kaneko Y, Hiromura K, Nojima Y. Expression of IL-19 and its receptors in RA: potential role for synovial hyperplasia formation. Rheumatology (Oxford) 2008;47(6):815&#x2013;820. doi: 10.1093/rheumatology/ken061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/ken061</ArticleId><ArticleId IdType="pubmed">18397956</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinert A, Linas I, Kaya B, Ibrahim M, Schlitzer A, Hruz P, Radulovic K, Terracciano L, Macpherson AJ, Niess JH. The stimulation of macrophages with TLR ligands supports increased IL-19 expression in inflammatory bowel disease patients and in colitis models. J Immunol. 2017;199(7):2570&#x2013;2584. doi: 10.4049/jimmunol.1700350.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1700350</ArticleId><ArticleId IdType="pubmed">28864472</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>